akba stock — Akebia Therapeutics (AKBA)

Akebia Therapeutics (AKBA) — Stock

akba stock refers to the Nasdaq-listed common shares of Akebia Therapeutics, a biopharmaceutical company focused on kidney-disease therapies. This article provides a practical, investor-focused guide to the company and akba stock: company background, where the shares trade, key market identifiers, historical price behavior, financial summary, business drivers and pipeline, governance and shareholder structure, analyst coverage, trading and derivatives details, regulatory and patent considerations, principal risks, recent news with dates, a timeline of material events, comparable peers and valuation context, and a curated list of resources to follow the stock. Readers will learn what typically moves akba stock, how to track live market data, and where to find official filings and investor materials. For execution, consider Bitget as a reliable trading venue and Bitget Wallet for custody.

Company overview

Akebia Therapeutics is a biopharmaceutical company that develops and commercializes therapies for kidney disease, with a focus on chronic kidney disease (CKD) indications. The company operates a product- and pipeline-led business model: it markets approved products where available and advances clinical-stage candidates through regulatory review and commercial partnerships. Akebia is headquartered in the United States and was founded to address underserved needs in nephrology.

Key commercial and pipeline assets that historically have driven the company's business profile include Auryxia (an oral iron-based therapy for certain CKD-related indications) and vadadustat (an oral HIF prolyl hydroxylase inhibitor developed for anemia of CKD). Partnerships, licensing agreements and commercial arrangements for these products have been material to Akebia’s revenue outlook and therefore to akba stock performance.

(For readers unfamiliar with clinical terms: Auryxia is a marketed therapy for dialysis-related hyperphosphatemia and iron deficiency in certain CKD patients; vadadustat is a development-stage oral anemia treatment intended to reduce the need for injectable ESA therapies. These product descriptions are high level and simplified for business context.)

Ticker and exchange listing

• Ticker symbol: AKBA
• Exchange: Nasdaq
• Currency of listing: U.S. dollars (USD)
• Primary market: Nasdaq Capital Market / Nasdaq Global Market (investors should verify listing tier on the day of interest)

Akebia’s ordinary shares trade under the ticker AKBA on Nasdaq. Historical listing events—such as the company's IPO and any subsequent corporate actions that affected the share count—are documented in the company's SEC filings and investor relations materials. Official intraday quotes and consolidated market data can be found via major financial data providers and the company’s investor relations announcements; for order execution and live trading, Bitget provides market access and real-time quotes for AKBA shares where available in your jurisdiction.

As of 2026-01-23, according to company disclosures and regulatory filings, investors should consult the latest SEC filings and Nasdaq market data for definitive listing facts and any recent corporate changes that could affect trading of akba stock.

Key stock identifiers and market data

Investors and analysts use a set of identifiers and market data points to monitor akba stock. Common items include:

• Market capitalization (market cap)
• Shares outstanding and basic/diluted shares
• Float (publicly available shares for trading)
• Ticker symbol (AKBA)
• Exchange (Nasdaq)
• Last trade price, bid/ask, and intraday volume
• 52-week high and low
• Average daily trading volume (liquidity indicator)
• Short interest and short ratio
• Option chains and derivatives activity (if options exist)

Primary data providers where investors commonly check these metrics include Nasdaq market data terminals, major financial portals and real-time trading platforms. For retail investors, Bitget provides live market data and execution access. Other sources for quotes and historical prices include mainstream market-data websites and the SEC EDGAR database for shares-outstanding and filings. Remember that values such as market cap and average volume change continuously; always confirm the timestamp of any quoted metric before making decisions related to akba stock.

Historical price performance

A complete historical performance review of akba stock should cover multiple timeframes and volatility patterns, including:

• Short-term performance: 1-day and 1-month moves that can reflect news, earnings, or trial results.
• Medium-term performance: Year-to-date (YTD) and 1-year returns to show recent trends and investor sentiment.
• Long-term performance: 5-year trends to contextualize the company's execution and structural valuation changes.
• 52-week high and low: useful for framing recent extremes.
• Notable runups and drawdowns: large percentage moves often driven by regulatory approvals, trial readouts, partnership announcements, or earnings surprises.
• Typical volatility and average trading volume: biopharmaceutical names can exhibit above-average volatility around binary events (trial results, FDA decisions).

Price moves in akba stock have historically been linked to clinical and regulatory developments, commercial launches or partnership updates. For example, positive clinical data, favorable regulatory decisions, or stronger-than-expected sales for approved products typically correlate with price appreciation; conversely, negative trial results, regulatory setbacks or disappointing sales can lead to sharp declines. Trading volume often spikes around press releases and earnings reports.

Important: when reviewing historical charts and numeric performance for akba stock, verify that the data is adjusted for corporate actions such as stock splits, offerings or M&A events. Use time-stamped data from official sources; for intraday execution, confirm live quotes on Bitget and the consolidated tape.

Financial summary

A robust financial summary for akba stock includes the following sections:

• Revenue and revenue trends: historical revenue growth or decline, major revenue drivers (product sales, royalty or license revenue, collaboration revenues).
• Profitability: EBITDA trends, net income or net loss, and profit margins.
• EPS trends: basic and diluted earnings per share across recent quarters and fiscal years.
• Cash position and liquidity: cash, cash equivalents, short-term investments, and comparison to operating cash burn.
• Debt and capital structure: total debt, maturities, lease obligations and any off-balance-sheet commitments.
• Capital raises and dilution: any recent follow-on equity offerings, convertible securities or stock-based compensation affecting shares outstanding.

Investors should consult the company’s quarterly (10-Q) and annual (10-K) SEC filings for audited numbers and disclosures. As of 2026-01-23, the most recent quarterly and annual reports and associated investor presentations should be used as the primary source for up-to-date financial data for akba stock.

Note: This article does not provide live financial figures. For precise metric values (market cap, revenue by year, cash on hand), check the latest SEC filings and real-time quotes via Bitget or the company investor relations materials.

Business drivers and product pipeline

Akebia’s valuation and the performance of akba stock are sensitive to several company-specific business drivers:

• Product sales: Revenue from marketed products (for example, Auryxia where applicable) is the most direct driver of near-term revenue.
• Regulatory approvals and labeling: Approvals, indications expansions or label changes materially affect commercial opportunity and investor expectations.
• Clinical trial results: Positive or negative Phase 2/3 results for pipeline candidates (notably vadadustat or other nephrology-focused programs) often cause significant stock moves.
• Partnerships and commercial agreements: Collaborations with larger pharmaceutical companies, distributors, or dialysis providers can influence market access, pricing, and reach.
• Reimbursement and payer decisions: Coverage by Medicare, Medicaid and private payers in the U.S. and reimbursement decisions in other markets impact sales forecasts.
• Manufacturing and supply chain: Reliable supply for commercial products and cost of goods trends affect gross margins and profitability.

Lead products and pipeline notes (business context only):

• Auryxia: Historically a marketed product for kidney-related indications; product sales and formulary access are direct revenue drivers affecting akba stock.
• Vadadustat: An oral small-molecule HIF prolyl hydroxylase inhibitor developed for anemia of CKD. Clinical trial progress, regulatory submissions and any labeling outcomes are major catalysts for valuation.

Analysts model akba stock using scenario-based forecasts that attach probabilities to regulatory and commercial outcomes. Major catalyst dates—such as trial readouts, advisory committee meetings and regulatory decisions—are often highlighted in consensus models and drive trading around akba stock.

Corporate actions and governance

Investors in akba stock should review corporate governance disclosures and recent corporate actions, which include:

• Board composition and executive leadership: independence, relevant industry experience, and recent leadership changes.
• Insider holdings and reported insider transactions: director and officer ownership and recent buys or sells reported on Form 4.
• Equity issuances and dilution: any shareholder-authorized share increases, follow-on offerings, private placements, or equity grants.
• Share buybacks or dividends: biopharmaceutical companies with growing cash flows may implement repurchase programs, though many early-stage biotech firms do not.
• Stock splits or reverse splits: any adjustments to the share base are material to historical pricing comparisons.

Changes in governance or equity structure can materially affect investor perception and liquidity in akba stock. Insiders increasing holdings are often noted by investors; conversely, frequent equity raises can lead to dilution concerns.

Major shareholders and ownership

Understanding ownership helps explain trading dynamics in akba stock:

• Institutional ownership: percentage of shares held by mutual funds, hedge funds, and institutional investors. Large institutional positions can mean concentrated ownership and affect float liquidity.
• Insider ownership: percentage held by executives, board members and founders; insider ownership can align incentives but also concentrate voting power.
• Notable holders: large funds or strategic investors disclosed in the company’s proxy statements.

Shifts in ownership—such as block trades, activist involvement, or strategic investor participation—can influence the stock through signaling effects or via formal proposals that require shareholder votes. Events such as shareholder authorization to increase shares outstanding or issuance approvals are directly relevant to holders of akba stock.

Analyst coverage and price targets

Analysts covering akba stock typically publish research notes that include ratings (e.g., buy/hold/sell), price targets and model assumptions. Commonly referenced firms in biotech coverage include full-service investment banks and independent research houses. Key points for readers:

• Consensus ratings and price targets: aggregated views can be useful but are updated periodically and can diverge widely for companies with binary clinical outcomes.
• Recent upgrades/downgrades: changes in ratings often coincide with trial readouts or regulatory news and can move akba stock.
• How to interpret analyst research: analysts’ models rely on clinical and commercial assumptions; treat price targets as one input rather than definitive forecasts.

Sources of analyst commentary include sell-side research and independent equity research platforms. For execution and monitoring, Bitget provides access to market data and news to help investors follow analyst updates relevant to akba stock.

Trading details and derivatives

Key trading and market microstructure items to consider for akba stock:

• Liquidity: typically measured by average daily volume and bid/ask spreads. High spreads and low volume increase execution risk.
• Options: presence of listed options (puts and calls) lets traders express views on volatility and directional risk. Options volume and open interest show where interest is concentrated.
• Short interest and short ratio: the absolute number of shares sold short and the short-interest ratio (days to cover) indicate bearish positioning and potential squeezes.
• Bid/ask dynamics: tightness of the bid/ask spread affects cost of trading, especially for large orders.

Biotech stocks can experience episodes of elevated implied volatility around clinical and regulatory events, which can increase option premiums and affect trading strategies. If options are available for akba stock, traders commonly use spreads and hedged structures to manage event risk.

Regulatory, legal and patent considerations

Several regulatory and legal topics are material to akba stock valuation:

• Regulatory approvals: FDA (U.S.) and EMA (EU) decisions, advisory committee outcomes, and post-marketing study requirements are critical for commercial prospects.
• Post-marketing commitments: approvals frequently carry post-approval study obligations that may affect labeling and market access.
• Intellectual property and patents: patent life, exclusivity periods and freedom-to-operate for lead products influence competitive positioning and long-term revenue potential.
• Competition and generics: the entry of alternative therapies, biosimilars or generics can materially compress pricing and market share.
• Legal proceedings: material litigation, product liability claims or government investigations can cause unexpected liabilities and reputational effects.

Investors should review SEC filings and the company’s risk disclosures for current legal proceedings and patent status. These filings provide detail on pending suits, license disputes or patent challenges that may affect akba stock.

Risks and investment considerations

This section lists principal investment risks related to akba stock in concise form. This is informational and not investment advice.

• Clinical and regulatory risk: failure in clinical trials or unfavorable regulatory decisions can lead to sharp downside moves.
• Commercialization risk: limited payer coverage, pricing pressure, or slow uptake by prescribers can reduce revenue expectations.
• Competition and generics: competing therapies or loss of exclusivity can erode market share.
• Funding and liquidity risk: biotech companies may need additional capital to fund operations; equity raises dilute existing holders if executed.
• Execution risk: manufacturing, supply chain, or partner-relationship failures can impair product availability and revenues.
• Volatility risk: biotech stocks often show heightened volatility, especially around binary events.

Investors commonly incorporate these risks into valuation models by applying probability-weighted outcomes to regulatory milestones, adjusting discount rates for binary risk, and monitoring cash runway to estimate dilution risk for akba stock.

Recent events and news highlights

The section below chronicles types of recent events that have historically moved akba stock. For time-stamped accuracy, readers must check the original press releases, SEC filings and investor presentations.

• As of 2026-01-23, according to company investor relations and SEC filings, investors should consult the latest quarterly earnings release for up-to-date revenue and cash position disclosures that influence perceptions of akba stock.
• Clinical trial readouts, regulatory submissions or decisions: any press release announcing Phase 3 results, FDA correspondence or approval decisions for vadadustat or other candidates typically drives significant moves in akba stock.
• Partnership or licensing announcements: new agreements expanding commercialization or regional distribution affect revenue forecasts and investor sentiment.
• Earnings reports and guidance updates: quarterly results and management guidance recalibrate analyst models for akba stock.
• Corporate governance updates: changes in the board, executive team, or insider transactions are commonly disclosed in proxy statements and Forms 4/5.

When monitoring news for akba stock, use the official investor relations feed, SEC EDGAR filings and reputable market-data providers. Bitget’s news and real-time quote features can help surface market-moving headlines for execution-ready users.

Timeline of significant stock-related events

A chronological timeline helps trace how company milestones have affected akba stock price action. Important event types include:

• IPO and listing date on Nasdaq
• Initial commercial launches of marketed products
• Key clinical trial milestones (start, readouts, primary endpoint results)
• Major regulatory milestones (submissions, approvals, CRLs, advisory committee votes)
• Significant partnership, licensing deals, or acquisitions
• Share issuance events, reverse/forward splits or buyback program announcements
• Notable analyst initiations or material target revisions

For precise dates and descriptions of each event that has impacted akba stock, consult the company’s investor relations timeline and SEC filings; these sources provide authoritative, timestamped records.

Comparative valuation and peers

When valuing akba stock, analysts typically compare the company to peers in nephrology and mid‑stage biotech. Common metrics used include:

• Price-to-sales (P/S): used for companies with limited profits but measurable revenues.
• Enterprise value-to-revenue (EV/Revenue): helps compare companies with differing capital structures.
• Price-to-earnings (P/E): applicable if the company reports positive, sustainable earnings.
• Pipeline-adjusted or probability-weighted revenue models: incorporate chances of regulatory success and peak sales estimates for pipeline assets.

Peer selection should focus on companies with similar product portfolios (renal-focused therapies), similar development-stage assets (HIF pathway drugs or iron-based therapies), and comparable commercial footprints. Relative valuation also considers payer coverage, pricing environment and market access dynamics unique to nephrology.

How to follow the stock (investor resources)

Recommended resources to track akba stock include:

• Company investor relations materials and press releases (official announcements and presentations)
• SEC EDGAR filings: 10-K, 10-Q, 8-K, proxy statements and Form 4s for insider transactions
• Real-time market data and execution: Bitget provides live quotes, order execution and market tools suitable for trading akba stock
• Financial portals and data services for charts and historical data (use sources that clearly mark data as delayed or real-time)
• Analyst reports and sell-side research for model assumptions and consensus estimates
• News aggregators and press coverage for event-driven headlines

Note: always verify whether a data feed is real-time or delayed, and cross-check critical data points with official filings before acting on information about akba stock.

See also

• Biotech investing basics
• Drug development pipeline stages and clinical trial phases
• Nasdaq market structure and trading mechanics
• Understanding SEC filings and corporate disclosures

References and external links

This article draws on public financial disclosures, company investor relations materials and mainstream market-data providers. Readers should consult the following primary sources for detail and verification (no direct links provided here):

• Akebia Therapeutics investor relations and press release archive (company web site)
• SEC EDGAR filings for Akebia Therapeutics (10-K, 10-Q, 8-K, Form 4)
• Nasdaq market data and ticker listing information (Nasdaq official site)
• Major financial data providers and market feeds for quotes and historical prices
• Recent analyst reports and broker research notes (for consensus estimates and price-target context)

As of 2026-01-23, company press releases and SEC filings are the authoritative sources for material events affecting akba stock.

If you want to track or trade akba stock, consider using Bitget for live market access and Bitget Wallet for secure custody. Explore company filings and the latest investor presentations before making trading decisions.

Appendix

Glossary of financial and clinical terms

• Market cap: Market capitalization, the market value of a company's outstanding shares.
• Float: The number of shares available for public trading (excluding restricted shares).
• EPS: Earnings per share, a profitability metric of net income divided by shares outstanding.
• Phase 2/3 trial: Mid-to-late stage clinical trials that assess efficacy and safety before potential regulatory approval.
• FDA: U.S. Food and Drug Administration, the primary regulator for drug approval in the United States.

Historical data tables and charts

This article omits embedded numeric tables. For price history tables, revenue by year and illustrative charts (price, volume, revenue trends) consult the company’s investor relations materials, SEC filings and market-data providers. Ensure that any data you use for akba stock is time-stamped and sourced.

Further exploration: to stay current on akba stock, set alerts for company 8-K filings, press releases and earnings calls. For trade execution and live market data, consider Bitget’s platform and check Bitget Wallet for secure custody options.